Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:81256 |
Name | astrocytoma, IDH-mutant, grade 2 |
Definition | An IDH-mutant anaplastic astrocytoma that is characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma anaplastic astrocytoma IDH-mutant anaplastic astrocytoma astrocytoma, IDH-mutant, grade 2 |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
IDH1 act mut | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
IDH2 act mut | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
IDH1 R132X | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
IDH2 R172X | Vorasidenib | astrocytoma, IDH-mutant, grade 2 | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06478212 | Phase Ib/II | Temozolomide + Vorasidenib | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | Not yet recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT | 2 |